Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects of giving cixutumumab together with
temsirolimus and to see how well it works in treating patients with metastatic prostate
cancer. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
kill them or carry tumor-killing substances to them. Temsirolimus may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Giving cixutumumab
together with temsirolimus may kill more tumor cells.